Additionally, researchers have determined that the BCR-ABL-independent activation of ERK1/2 contributes to imatinib resistance in K562/R cells and that ERK1/2 could be targeted for treatment in CML patients with imatinib resistance due to this mechanism [33]. This evidence concerns the gene MAPK3 and chronic myelogenous leukemia, BCR-ABL1 positive.